Related by context. All words. (Click for frequent words.) 71 obatoclax 68 ganetespib 68 Cloretazine R VNP#M 68 tanespimycin 68 enzastaurin 68 neratinib 68 OncoVEX GM CSF 67 nab paclitaxel 67 Onrigin 67 PXD# 67 pertuzumab 67 relapsed multiple myeloma 67 elotuzumab 67 CoFactor 67 oral ridaforolimus 66 alvespimycin 66 aflibercept VEGF Trap 66 Cloretazine 66 celgosivir 66 Dacogen injection 66 vinorelbine 65 ixabepilone 65 INCB# [001] 65 sunitinib malate 65 cilengitide 65 MAGE A3 ASCI 65 docetaxel Taxotere 65 forodesine 65 Virulizin ® 65 KRN# 65 docetaxel Taxotere R 65 sapacitabine 65 Phase Ib II 65 pomalidomide 65 lintuzumab 64 Panzem R NCD 64 IMA# 64 relapsed refractory multiple myeloma 64 registrational 64 voreloxin 64 tesmilifene 64 custirsen 64 axitinib 64 Phase Ib 64 Cloretazine ® 64 Ketotransdel 64 antithrombotics 64 HuMax EGFr 64 HGS# 64 romidepsin 64 phase IIb clinical 64 PSMA ADC 64 glufosfamide 64 indibulin 64 MGd 64 PROVENGE sipuleucel T 64 trabectedin 64 Pemetrexed 64 BAY #-# 64 metastatic renal cell carcinoma 64 TREANDA 64 eniluracil 64 galiximab 63 idarubicin 63 otelixizumab 63 Onrigin TM 63 liposomal formulation 63 gemcitabine 63 Azedra 63 Taxotere ® 63 dacetuzumab 63 Phase Ib study 63 picoplatin 63 noninfectious uveitis 63 mRCC 63 CBLC# 63 HuLuc# 63 HER2 positive metastatic breast 63 ponatinib 63 docetaxel chemotherapy 63 PRT# 63 ELACYT 63 Allovectin 7 63 belinostat 63 vascular disrupting agent 63 Targretin 63 adecatumumab 63 ADVEXIN 63 phase IIb trial 63 pazopanib 63 vidofludimus 63 vosaroxin 63 liposomal doxorubicin 63 Phase 2b clinical 63 platinum refractory 63 metaglidasen 63 LHRH antagonists 63 sargramostim 63 talactoferrin 63 JAK inhibitor 63 sorafenib Nexavar ® 63 Alocrest 63 entinostat 63 sorafenib tablets 63 torezolid phosphate 63 phase IIb 63 opioid induced bowel dysfunction 63 paclitaxel Taxol ® 63 relapsed ovarian cancer 63 CR# vcMMAE 63 Bortezomib 63 imetelstat 62 deforolimus 62 CLORETAZINE TM VNP#M 62 alkylating agent 62 rNAPc2 62 TORISEL 62 REOLYSIN ® 62 OXi# 62 bevacizumab Avastin ® 62 NVA# 62 elacytarabine 62 sorafenib Nexavar 62 XL# SAR# 62 decitabine 62 HGS ETR1 62 Targretin capsules 62 cangrelor 62 ONCONASE 62 GRN#L 62 oxymorphone ER 62 FOLOTYN ® 62 Amigal 62 AP# [003] 62 Fibrillex TM 62 Bicifadine 62 R roscovitine 62 MGCD# [001] 62 Phase Ib clinical 62 standard chemotherapy regimen 62 gemcitabine cisplatin 62 elesclomol 62 APF# 62 Phase IIa trials 62 trastuzumab DM1 T DM1 62 OvaRex ® MAb 62 INCB# [002] 62 Seliciclib 62 ARIKACE ™ 62 viral kinetics 62 rALLy clinical trial 62 PEG SN# 62 APTIVUS 62 lumiliximab 62 EFAPROXYN 62 T DM1 62 AEG# 62 IMGN# 62 IRX 2 62 carboplatin paclitaxel 62 oral prodrug 62 Xanafide 62 HGS ETR2 62 MyVax R 62 teriflunomide 62 VNP#M 62 TELINTRA 62 vicriviroc 62 Gemzar ® 62 Neuradiab 62 oral talactoferrin 62 cediranib 62 pan HDAC inhibitor 62 Vilazodone 62 lorvotuzumab mertansine 62 temsirolimus 62 FOLFIRI 62 riociguat 62 investigational humanized monoclonal antibody 62 investigational monoclonal antibody 62 CALGB # [002] 62 nitazoxanide 62 phase IIa clinical 62 CA4P 62 YONDELIS 62 Doxil 62 gemcitabine Gemzar ® 62 pegylated interferons 61 trastuzumab emtansine T DM1 61 Amrubicin 61 indolent NHL 61 Imprime PGG 61 vandetanib 61 vinca alkaloid 61 perifosine 61 ONCONASE R 61 metastatic HRPC 61 Ophena TM 61 EndoTAG TM -1 61 visilizumab 61 PREOS 61 Tyrima 61 doxorubicin docetaxel 61 EOquin TM 61 TBC# 61 DAVANAT 61 subcutaneous formulation 61 crizotinib PF # 61 pemetrexed 61 CYT# potent vascular disrupting 61 EVIZON 61 CANCIDAS 61 carfilzomib 61 Fludara 61 Treanda 61 low dose cytarabine 61 Sym# 61 LEP ETU 61 SUTENT ® 61 Phase 2b study 61 OPAXIO 61 GALNS 61 Doxil ® 61 L BLP# 61 Zenvia ™ 61 HCV protease inhibitor 61 PROSTVAC TM 61 uric acid lowering 61 MAA submission 61 Phase 1b 61 Telatinib 61 XmAb# 61 FOLFOX6 chemotherapy regimen 61 registrational trial 61 PSN# [002] 61 Allovectin 7 ® 61 ATL/TV# 61 EndoTAGTM 1 61 VELCADE melphalan 61 mapatumumab 61 OHR/AVR# 61 pralatrexate 61 farletuzumab 61 dacarbazine 61 CRMD# 61 tipifarnib 61 SCCHN 61 BCX# 61 tipranavir 61 ZOLINZA 61 velafermin 61 histone deacetylase HDAC inhibitor 61 paclitaxel Taxol 61 CINTREDEKIN BESUDOTOX 61 Hyphanox 61 placebo controlled Phase III 61 regorafenib 61 bazedoxifene 61 taxane 61 DermaVir Patch 61 Trastuzumab 61 Phase #b/#a clinical 61 Traficet EN 61 anticancer compound 61 pegylated interferon alpha 61 oritavancin 61 mertansine 61 HspE7 61 trabedersen 61 cytarabine 61 cannabinor 61 RSD# oral 61 Phase 1b clinical 61 relapsed SCLC 61 pegylated interferon alfa 2b 61 trastuzumab Herceptin ® 61 MERLIN TIMI 61 BRAF inhibitor 61 glatiramer acetate 61 APTIVUS r 60 afatinib 60 Octreolin 60 ZYBRESTAT 60 proteasome inhibitor 60 Trofex 60 Symadex 60 #I TM# 60 corticosteroid dexamethasone 60 Phase 1b trial 60 Phase IIIb clinical 60 AQ4N 60 TYKERB 60 assessing T DM1 60 balsalazide tablet 60 Zerenex 60 BrachySil TM 60 Aplidin 60 oral rivaroxaban 60 ZK EPO 60 AKT inhibitor 60 ongoing Phase 1b 60 Temsirolimus 60 heavily pretreated 60 TELCYTA 60 cell lymphoma CTCL 60 recurrent GBM 60 evaluating tivozanib 60 lesinurad 60 angiogenesis inhibitor 60 INC# 60 IMC A# 60 EOquin 60 Ceflatonin 60 aflibercept 60 CYC# 60 MEK inhibitor RDEA# 60 ON #.Na 60 erlotinib Tarceva ® 60 ISTODAX 60 bortezomib Velcade 60 Velcade bortezomib 60 amrubicin 60 alvimopan 60 Apoptone 60 atacicept 60 sorafenib Nexavar R 60 pain palliation 60 MEND CABG II 60 sunitinib 60 radiation sensitizer 60 anti leukemic 60 varespladib 60 resistant ovarian cancer 60 temsirolimus Torisel ® 60 TheraSphere 60 bortezomib Velcade R 60 Altastaph 60 Ozarelix 60 Factor VIIa 60 resminostat 60 oral antiviral 60 pharmacodynamic PD 60 INT# [002] 60 superficial bladder cancer 60 MYCAMINE 60 Proxinium TM 60 Combo Stent 60 azacitidine 60 rHuPH# 60 refractory AML 60 Archexin 60 CLARITY study 60 Marqibo 60 EmbraceAC 60 Phase #b/#a 60 vismodegib 60 menadione 60 topotecan 60 CEQ# 60 BR.# 60 AAG geldanamycin analog 60 Amplimexon 60 NDA resubmission 60 cytotoxic chemotherapy 60 NATRECOR R 60 surrogate endpoint 60 erlotinib Tarceva 60 Erlotinib 60 RGB # 60 pharmacokinetic equivalence 60 Zybrestat 60 DOXIL 60 L MTP PE 60 virus HCV protease inhibitor 60 thymalfasin 60 LibiGel ® 60 Irinotecan 60 PEP# [003] 60 refractory Hodgkin lymphoma 60 bevacizumab Avastin 60 preclinical efficacy 60 NEBIDO 60 capecitabine Xeloda R 60 Poly ICLC 60 initiate Phase 1b 60 bendamustine 60 sipuleucel T 60 iniparib 60 VEGF Trap 60 TRO# 60 gemcitabine Gemzar 60 PLK1 SNALP 60 Talabostat 60 Carfilzomib 60 recurrent glioblastoma 60 Tarceva TM 60 pancreatic NET 60 Dyloject TM 60 treprostinil 60 zalutumumab 60 tecarfarin 60 ARIKACE 60 ThGRF 60 epigenetic therapies 60 Asentar 60 ridaforolimus 60 relapsed MM 60 RG# [001] 60 refractory metastatic 60 Gemcitabine 60 oral Xeloda 60 IL# PE#QQR 60 Phase IIB 60 Fx #A 60 Nexavar ® 60 favorable pharmacokinetic profile 60 relapsed AML 60 MEK inhibitor 60 Tamibarotene 60 ACTEMRA TM 60 Inhalation Solution 60 Lenocta 60 depsipeptide 60 paclitaxel Taxol R 60 tolevamer 60 PNP inhibitor 60 ProLindac TM 60 Voreloxin 60 LUX Lung 60 SUCCEED trial 60 dalbavancin 60 Aflibercept 60 gefitinib Iressa 60 IRESSA 60 confirmatory Phase III 60 fluoropyrimidine 60 anti angiogenic agents 60 trastuzumab Herceptin R 60 Bevacizumab 60 INTELENCE 60 phase Ib 60 recurrent glioblastoma multiforme 60 randomized Phase IIb 60 blinded randomized placebo controlled 59 NP2 Enkephalin 59 Panzem 59 oral treprostinil 59 boosted protease inhibitor 59 budiodarone 59 refractory metastatic colorectal cancer 59 EGS# 59 combretastatin A4 phosphate CA4P 59 Hycamtin 59 Phase 2a trial 59 Pegasys plus Copegus 59 Zevalin R Ibritumomab 59 vorinostat 59 pharmacokinetic PK study 59 AEGR 59 Degarelix 59 estramustine 59 R#/MEM # 59 huN# DM1 59 PrevOnco ™ 59 targeted radiotherapeutic 59 PI3K/Akt pathway inhibitor 59 UPLYSO 59 Pazopanib 59 relapsed myeloma 59 FASLODEX 59 fondaparinux 59 Vectibix monotherapy 59 CCR5 antagonist 59 Chemophase 59 remission induction 59 DAPT 59 Panzem R 59 gemcitabine chemotherapy 59 ThermoDox 59 ALGRX 59 FOLOTYN 59 ZEVALIN 59 AeroLEF TM 59 SUTENT 59 anticancer therapy 59 5 fluorouracil leucovorin 59 antiangiogenic therapy 59 TLK# 59 tigecycline 59 SinuNase 59 BRIM2 59 Phase IIb clinical 59 cutaneous T 59 Telintra 59 DEB# 59 Atiprimod 59 leucovorin 59 Prostate AdenoCarcinoma Treatment 59 Glufosfamide 59 refractory CLL 59 TACI Ig 59 ThermoDox R 59 efficacy tolerability 59 teduglutide 59 Hepatocellular Carcinoma HCC 59 cisplatin chemotherapy 59 Ceplene/IL-2 59 mifamurtide 59 antiangiogenic agents 59 relapsed refractory 59 PDE4 inhibitor 59 ISENTRESS 59 Pertuzumab 59 invasive candidiasis 59 cisplatin gemcitabine 59 CHOP chemotherapy 59 REG1 59 ALIMTA 59 oral FTY# 59 interferon gamma 1b 59 bicifadine 59 mCRC patients 59 leading oral taxane 59 FOLFOX6 59 CD3 monoclonal antibody 59 selective androgen receptor modulator 59 refractory multiple myeloma 59 octreotide implant 59 Phase III pivotal 59 Pegylated Interferon 59 seliciclib 59 eprotirome 59 CD# antibody [001] 59 Zemplar Capsules 59 CIMZIA TM 59 evaluating satraplatin 59 FavId 59 DACH platinum 59 Diabetic Macular Edema 59 bone metastases 59 relapsed MCL 59 lupus nephritis 59 Dapagliflozin 59 investigational hepatitis C 59 APTIVUS ritonavir 59 CIMZIA ™ 59 bosutinib 59 PRTX 59 metastatic CRC 59 IMPACT IMmunotherapy 59 Phase #/#a trial 59 ELOXATIN 59 refractory chronic lymphocytic 59 docetaxel Taxotere ® 59 antiplatelet 59 Phase 2b trial 59 NDA submission 59 APPRAISE 59 randomized Phase III 59 renal anemia 59 chemotherapeutic regimen 59 lupus renal disease 59 rhThrombin 59 infusional 5-FU/LV 59 phase 2a 59 velafermin belinostat 59 thalidomide Thalomid 59 Aryplase 59 ASA# 59 Pralatrexate 59 paclitaxel poliglumex 59 talabostat 59 Lixivaptan 59 NEUVENGE 59 proteasome inhibitor bortezomib 59 cardiac toxicity 59 castrate resistant prostate cancer 59 relapsing multiple sclerosis 59 Vidaza azacitidine 59 randomized Phase 2b 59 Alpharadin 59 Omacetaxine 59 ofatumumab 59 QVA# 59 TOCOSOL Paclitaxel 59 Viprinex TM 59 FOLFOX regimen 59 Pruvel 59 NATRECOR ® 59 IIa trial 59 Phase IIb clinical trials 59 LY# [003] 59 Taxotere R 59 TREDAPTIVE 59 docetaxel 59 Cloretazine R 59 SNT MC# 59 TKM ApoB 59 CaPre TM 59 Hsp# inhibitor 59 Troxatyl 59 Vicinium TM 59 ATL# [001] 59 gemcitabine carboplatin 59 acetonide FA 59 OMAPRO 59 Hsp# Inhibitor 59 dirucotide 59 FOLPI 59 HQK 59 MoxDuo IR 59 mycophenolate mofetil 59 fidaxomicin 59 canakinumab 59 MAP# 59 CRLX# 59 MOZOBIL 59 IMiDs R 59 pharmacokinetic PK 59 intravenously administered 59 DexaSite 59 Ixempra 59 PDX pralatrexate 59 R sorafenib tablets 59 reslizumab 59 Golimumab 59 Phenoptin 59 Valortim R 59 TEMODAL 59 Copegus ribavirin 59 vascular disrupting agents 59 GGF2 59 abatacept 59 CTAP# Capsules 59 PHX# 59 MNTX 59 pharmacodynamics PD 59 midstage clinical 59 peginterferon 59 direct thrombin inhibitors 59 daptomycin 59 mitomycin 59 nucleotide analog 59 investigational compound 59 seliciclib CYC# 59 Kamada AAT 58 viral kinetic 58 subcutaneous PRO 58 ISIS # 58 Junovan 58 antithrombotic 58 Xeloda ® 58 dose escalation clinical 58 dasatinib 58 immunomodulatory 58 chemoradiation 58 fosbretabulin 58 Civacir 58 cobiprostone 58 LE DT 58 eltrombopag 58 Stedivaze 58 chemoradiation therapy 58 solithromycin 58 Exelixis XL# 58 personalized immunotherapy 58 Zevalin consolidation 58 FOLFOX 58 BARACLUDE R 58 dextromethorphan quinidine 58 Gefitinib 58 oxaliplatin Eloxatin 58 chemotherapy docetaxel 58 NEUMUNE 58 Torisel 58 MEK inhibitors 58 RNAi therapeutic targeting 58 dasatinib Sprycel ® 58 antiangiogenic agent 58 Aptivus ® 58 posaconazole 58 HCV NS5B polymerase 58 TG# [003] 58 herpetic keratitis 58 unique alkylating agent 58 metastatic RCC 58 nucleoside 58 atrasentan 58 diarrhea predominant irritable 58 Virulizin R 58 pegylated interferon alfa 58 PD LID 58 systemically administered 58 anticancer agent 58 ACZ# 58 hematological malignancies 58 cytokine refractory 58 maximally tolerated dose 58 lenalidomide Revlimid R 58 Abiraterone acetate 58 metastatic colorectal cancer 58 multicenter Phase 58 CINQUIL 58 HDAC Inhibitor 58 Tavocept 58 DPP4 inhibitor 58 valopicitabine 58 PREZISTA r 58 Ambrisentan 58 PKC# 58 Triapine R 58 Taxotere docetaxel 58 PEG interferon 58 Entereg R 58 tolvaptan 58 ZACTIMA 58 TRISENOX 58 CAPHOSOL 58 Annamycin 58 MGCD# [002] 58 StemEx R 58 samalizumab 58 brentuximab vedotin 58 Dalbavancin 58 melphalan prednisone 58 cathepsin K inhibitor 58 Plicera 58 QuadraSphere 58 pharmacokinetics pharmacodynamics 58 CIMZIA TM certolizumab pegol 58 hematological cancers 58 bortezomib 58 Revlimid lenalidomide 58 miconazole Lauriad ® 58 ribavirin RBV 58 immunomodulator 58 BEMA TM Fentanyl 58 TASKi2 58 RSR# 58 MYDICAR ® 58 antithrombotic therapy 58 subcutaneously administered 58 AGGRASTAT ® 58 cutaneous T cell 58 BIBW 58 GLP toxicology studies 58 metastatic renal cell 58 PROVENGE ® 58 ChronVac C ® 58 PrevOnco 58 Nexavar sorafenib 58 mCRC 58 Phase Ib clinical trials 58 Intravenous CP 58 phase IIa 58 NXL# 58 Mipomersen 58 huC# DM4 58 immunotherapeutic agent 58 pegfilgrastim 58 Saforis 58 AZILECT ® 58 phase IIb study 58 clevidipine 58 Xcytrin R 58 multicenter Phase II 58 ZYBRESTAT fosbretabulin 58 formoterol fumarate 58 non metastatic osteosarcoma 58 chemoradiotherapy 58 BEXXAR 58 systemic anaplastic large 58 brivaracetam 58 coronary stent merged 58 intravesical infusion therapy 58 Guanilib 58 non nucleoside HCV 58 Romidepsin 58 abiraterone acetate 58 IAP inhibitors 58 Peginterferon 58 IND submission 58 OvaRex R 58 APEX AMI trial 58 severe gastroparesis 58 midstage trials 58 Azedra TM 58 INTEGRILIN 58 angiogenesis inhibition 58 MIRCERA 58 histone deacetylase inhibitor 58 metastatic hormone refractory 58 HyQ 58 Deforolimus 58 IMC #B 58 blinatumomab 58 EXPAREL ™ 58 plus gemcitabine 58 DXL# 58 Folfox 58 HuMax CD4 58 Tarceva erlotinib 58 Icatibant 58 intravenous cyclophosphamide 58 ritonavir boosted danoprevir 58 Methylnaltrexone 58 Zingo TM 58 UVIDEM 58 SABCS 58 figitumumab 58 Phase 2a clinical 58 JAK2 inhibitor 58 predictive biomarker 58 ancrod 58 Kahalalide F 58 platelet inhibitor 58 trodusquemine 58 biologic therapy 58 Voraxaze ™ 58 Genasense 58 efficacy endpoint 58 RAPAFLO 58 5-FU/LV 58 torsemide ER 58 lapatinib Tykerb 58 pegylated liposomal doxorubicin 58 randomized multicenter Phase III 58 SCH # 58 TAXOTERE R 58 Optiquel ™ 58 rilonacept 58 Aclidinium 58 postoperative ileus POI 58 tezampanel 58 CRF1 receptor antagonist 58 Quinamed 58 receptor tyrosine kinase inhibitor 58 mTOR inhibitor 58 PREZISTA rtv 58 Dacogen decitabine 58 Phase 1a clinical 58 Fludara ® 58 zanolimumab 58 ALN PCS 58 Anavex #-# 58 registrational Phase 58 ILUVIEN ® 58 PEG PAL 58 nalbuphine ER 58 FTY# 58 lomitapide 58 refractory angina 58 Exherin TM 58 HoFH 58 Octreotide 58 PROCHYMAL 58 prostate cancer HRPC 58 Androxal TM 58 DAVANAT R 58 Elotuzumab 58 ospemifene 58 BLA filing 58 idiopathic pulmonary fibrosis IPF 58 lymphoma CTCL 58 severe hypercholesterolemia 58 Natalizumab 58 Resten NG 58 Viprinex 58 Alvesco R 58 Tanespimycin 58 Vandetanib 58 carboplatin 58 Neulasta ® 58 panitumumab 58 icatibant 58 antibody MAb 58 metastatic castration resistant 58 non squamous NSCLC 58 ADVEXIN therapy 58 catheter occlusion 58 Darusentan 58 SPRYCEL ® 58 dose escalation 58 BrachySil 58 NOXAFIL 58 generation purine nucleoside 58 aerosolized KL4 surfactant 58 tocilizumab 58 invasive aspergillosis 58 Xelox 58 HRPC 58 ACAPODENE 58 lenalidomide dexamethasone 58 PS# [001] 58 Defibrotide 58 MT# MEDI 58 Vicriviroc 58 liposomal amphotericin B 58 biologic DMARD 58 Proellex TM 58 plus DOXIL 58 novel histone deacetylase 58 pan histone deacetylase 58 iSONEP 58 lexidronam injection 58 iclaprim 58 SAR# [004] 58 BAL# [002] 58 refractory colorectal cancer 58 epothilone 58 rFVIIa 58 ThermoDox ® 58 QLT# 58 HCV protease inhibitors 58 Reolysin 58 Acute Ischemic Stroke 58 tesetaxel 58 Personalized Immunotherapy 58 APEX PD 58 Aviptadil 58 plus prednisone 58 PRX# 58 dextofisopam 58 dasatinib Sprycel 58 Pimavanserin 58 locoregional 58 PEG Interferon lambda 58 XL# XL# XL# 57 bosentan 57 nanopharmaceutical 57 hoFH 57 oblimersen 57 sNDA submission 57 OZURDEX ® 57 Elagolix 57 HSP# inhibitor 57 Telavancin 57 ApoB SNALP 57 paclitaxel carboplatin 57 Fodosine 57 orally bioavailable 57 somatostatin analogues 57 evaluating Nexavar 57 tumor lysis syndrome 57 XL# [003] 57 chemotherapy FOLFOX 57 etoposide 57 DOS# 57 Zenvia TM 57 ChronVac C R 57 novel topoisomerase 57 Perifosine 57 amifampridine phosphate 57 hypoxia activated prodrug 57 nucleoside analogues 57 Ranolazine 57 Prestara 57 Myocet 57 lasofoxifene 57 PROSTVAC ® 57 Metastatic Melanoma 57 investigational drug 57 temozolomide 57 drug conjugate 57 cancer immunotherapies 57 ruxolitinib 57 Ceflatonin R 57 myelofibrosis 57 tolerability pharmacokinetics 57 JAK inhibitors 57 advanced NSCLC 57 ILLUMINATE 57 triphendiol 57 PRECISE trial 57 pharmacodynamic effects 57 lintuzumab SGN 57 metastatic colorectal 57 including eniluracil ADH 57 Folotyn 57 5 Fluorouracil 57 VAPRISOL 57 peginterferon alfa 2b 57 Tarvacin TM 57 IAP inhibitor 57 EGFR TKI 57 Specifid 57 Phase III randomized controlled 57 Capesaris 57 antitumor activity 57 deferiprone 57 Tasimelteon 57 AzaSite Plus 57 Plenaxis TM 57 Betaferon ® 57 dose cohort 57 oxypurinol 57 Telaprevir 57 LEVADEX 57 limiting toxicity